Lumiliximab

A4DAB161 | Phase-II

Target FCER2/CD23

Isotype / Subclass G1 / None

Company

Biogen Idec

Clinical Status Phase-II

Format Whole mAb

Synonyms

IDEC-152 IDEC152 IDEC 152 ST-152 ST152 ST 152

pH Formulation —

IMGT PubChem (135273044) PubChem (160698505) PubChem (404770124) PubChem (472386538) PubChem (474488739) PubChem (474489089) PubChem (498138006) PubChem (505778352) PubChem (513905275) Thera-SAbDab YAbS

Avg A4D Score

-0.767

Score Range

-0.78 to -0.76

Structures

Avg. A4D Score per Structure

pH at Min / Max Aggregation Propensity

Structure ID	Source PDB	Seq. Identity	Avg. A4D Score	pH (Min Agg.)	pH (Max Agg.)	Score CDR	Score non-CDR
A4DAB161_3fzu_C_D	3fzu	99%	-0.7572	6.5	4.0	-0.5699	-0.7792
A4DAB161_3fzu_H_L	3fzu	99%	-0.7768	6.5	4.0	-0.6457	-0.7922

Lumiliximab

Avg. A4D Score per Structure

pH at Min / Max Aggregation Propensity

Associated Structural Profiles Level 2